SEATTLE, April 15, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present data demonstrating how profiling a patient's T-cell repertoire may inform clinical care in patients with melanoma and other solid tumors at the American Association for Cancer Research® (AACR) meeting in Philadelphia from April 18-22, 2015.
Adaptive's core immunoSEQ™ platform technology utilizes high-throughput, bias-controlled sequencing to profile T- and B-cell receptors, enabling in-depth characterization of the adaptive immune response against cancer.
Demonstrating the clinical significance of immune profiling to comprehensively study patients with metastatic disease, data will be presented highlighting the heterogeneity of the immune repertoire from site to site in patients with melanoma.
Profiling the T-cell repertoire is also being widely incorporated into clinical studies to assess the efficacy of treatments specifically designed to induce an immune response to cancer, including checkpoint inhibitors such as anti-CTLA, dendritic cell vaccines, and vaccination with patient-specific tumor-derived neoantigens. Of particular significance is a study explaining how resistance to anti-CTLA4 therapy can be overcome by concurrent local radiotherapy (RT). Using the immunoSEQ™ Assay, the study demonstrates that coupling these therapies results in a broader repertoire of tumor-specific T cells, which contribute to tumor rejection.
"The studies presented at AACR this year using the immunoSEQ™ Platform highlight the importance of monitoring the dynamic and inducible T-cell repertoire to contribute to the continued development of cancer immunotherapy regimens," says Dr. Harlan Robins, CSO and Co-Founder of Adaptive Biotechnologies. "In response to these data and others, Adaptive is increasingly committed to exploring how the quantification of T-cell responses to cancer and to treatments for cancer may become a universally applicable clinical tool for patients with solid tumors."
Representatives from Adaptive Biotechnologies will be exhibiting at AACR (booth #649) to answer questions about its immunosequencing technology.
Oral presentation highlighting the utility of immunoSEQ™ in understanding immunotherapy mechanisms of action:
Abstract #2856: Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
Presenter: Karsten Pilones
Session: Mini-symposium: Immune Checkpoint Inhibition
Time: Monday, April 20, 2015, 3:20 PM – 3:35 PM
Location: Terrace Ballroom IV (400 Level), Pennsylvania Convention Center
Posters demonstrating value of the immunoSEQ™ Platform in clinically relevant research:
Abstract # LB-237: Vaccination increases the breadth and diversity of melanoma neoantigen-specific T cells in humans
Presenter: Beatriz M. Carreno
Session: Late-Breaking Research: Immunology
Time: Tuesday, April 21, 1:00 PM – 5:00 PM
Location: Section 39
Abstract # 1301: Inter- and intra-tumoral immune and genomic heterogeneity in patients with metastatic melanoma
Presenter: Alexandre Reuben
Session: Human Immunity and Immune Correlates
Time: Monday, April 20, 8:00 AM – 12:00 PM
Location: Section 11, Poster Board #30
Abstract # 2499: Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers
Presenter: Vivek Subbiah
Session: Tumor Vaccines
Time: Monday, April 20, 1:00 PM – 5:00 PM
Location: Section 26, Poster Board #11
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ™ brand name. The immunoSEQ™ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.
Adaptive's first clinical application, the two-step clonoSEQ™ Process, enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid cancers (blood cancers). Clinical validation studies have shown that clonoSEQ™ MRD Test offers significant improvements in sensitivity and performance over other MRD detection methods. ClonoSEQ™ Test results are generated in Adaptive's CLIA-certified, CAP-accredited laboratory and provided to the ordering physician in a simple, actionable report via a secure online portal.
The company is also validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.
SOURCE Adaptive Biotechnologies Corporation